Organon & Co | Les Charges D'Exploitation



Operating Expenses Changement Date
Adcock Ingram Holdings ZAR 4.42B 268.95M 2024-06
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Celltrion KRW 674.25B 128.01B 2024-09
Cspc Pharmaceutical CNY 5.42B 102.74M 2024-09
Dianthus Therapeutics USD 33.24M 1.17M 2024-12
Ecofibre AUD 12.31M 44.07M 2024-06
Gilead Sciences USD 5.12B 1.54B 2024-12
Glaxosmithkline GBP 7.42B 408M 2024-12
Kangmei Pharma CNY 1.46B 193.63M 2024-09
Knight Therapeutics CAD 89.06M 2.02M 2024-09
Laboratorios Farma EUR 311.35M 170.35M 2024-12
Malin Corporation EUR 700K 1.6M 2024-06
Medical Developments International AUD 10.35M 17.73M 2024-06
Merck USD 11.33B 1.4B 2024-12
Neuren Pharmaceuticals AUD 17.41M 2.86M 2024-12
Novartis USD 10.15B 579M 2024-12
Organigram Holdings CAD 54.04M 9.62M 2024-12
Organon & Co USD 1.46B 88M 2024-12
Pharma Mar EUR 43.47M 3.3M 2024-12
Qiagen NV USD 377.04M 4.6M 2024-12
Sartorius EUR 725.4M 29M 2024-09
Sino Biopharmaceutical CNY 11.66B 5.46B 2024-12
Tilray USD 253.17M 16.55M 2024-11



Organon & Co Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.